drugset / Trial / NCT03408574

The Nicotinic Cholinergic System and Cognitive Aging

NCT03408574

RandomizedParallel-groupTriple-blindBasic science

Summary

Prior research has shown that a chemical system in the brain called the cholinergic system is primarily responsible for cognitive symptoms seen in people with dementia. While therapeutic benefits are clear in dementia, what remains uncertain is the role that the cholinergic system in general and a subset of receptors called the nicotinic system plays in cognition in healthy non-demented older adults (referred to as normal cognitive aging). This is critical because the ever growing healthy aging population will show declines in cognition that fall short of dementia but still impact functional abilities and independence. Maintaining good nicotinic system functioning throughout adulthood may lessen the cognitive symptoms of aging. At this time, it is not clear what the biological cause of age-related changes in cognition is. This study will examine the role of the nicotinic system in the healthy aging brain and examine its role in memory and thinking processes in older and younger adults.

Timeline

Start
2016-10-01
Primary completion
2021-12-01
Completion
2022-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Mecamylamine Small molecule Oral
Subject Nicotine Unknown

Indications

No indication recorded.